The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells.

Transforming growth factor beta (TGF-beta) can act as suppressor and promoter of cancer progression. Intracellular Smad proteins (i.e., receptor regulated Smads and common mediator Smad4) play a pivotal role in mediating antimitogenic and proapoptotic effects of TGF-beta, but their function in TGF-beta-induced invasion and metastasis is unclear. Here, we have investigated the role of Smad4 in a cellular and mouse model for TGF-beta-induced breast cancer progression. Consistent with its tumor suppressor function, specific silencing of Smad4 in NMuMG mammary gland epithelial cells using small hairpin RNA (shRNA)-expressing RNAi vectors strongly mitigated TGF-beta-induced growth inhibition and apoptosis. Smad4 knockdown also potently inhibited TGF-beta-induced epithelial to mesenchymal transition of NMuMG cells as measured by morphologic transformation from epithelial to fibroblast-like cells, formation of stress fibers, inhibition of E-cadherin expression, and gain of expression of various mesenchymal markers. Furthermore, we show that knockdown of Smad4 in MDA-MB-231 breast cancer cells strongly inhibited the frequency of bone metastasis in nude mice by 75% and significantly increased metastasis-free survival. Communication of MDA-MB-231 cells with the bone microenvironment, which is needed for optimal tumor cell growth and metastasis, may be affected in Smad4 knockdown cells as TGF-beta-induced expression of interleukin 11 was attenuated on Smad4 knockdown. Taken together, our results show that Smad4 plays an important role in both tumor suppression and progression of breast cancer cells.

[1]  Wei He,et al.  Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  C. Hill,et al.  Smad4 Dependency Defines Two Classes of Transforming Growth Factor β (TGF-β) Target Genes and Distinguishes TGF-β-Induced Epithelial-Mesenchymal Transition from Its Antiproliferative and Migratory Responses , 2005, Molecular and Cellular Biology.

[3]  Ivo Que,et al.  Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. , 2005, Cancer research.

[4]  Xunbin Wei,et al.  In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment , 2005, Nature.

[5]  C. Heldin,et al.  TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. , 2005, Molecular biology of the cell.

[6]  Gerard C Blobe,et al.  Role of transforming growth factor Beta in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Keith R. Johnson,et al.  Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition , 2005, Journal of Cell Science.

[8]  Abraham Schneider,et al.  Skeletal Localization and Neutralization of the SDF‐1(CXCL12)/CXCR4 Axis Blocks Prostate Cancer Metastasis and Growth in Osseous Sites In Vivo , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  P. Dijke,et al.  New insights into TGF-β–Smad signalling , 2004 .

[10]  Reuven Agami,et al.  A large-scale RNAi screen in human cells identifies new components of the p53 pathway , 2004, Nature.

[11]  L. Wakefield,et al.  Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. , 2003, Cancer research.

[12]  Jonas Larsson,et al.  Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. , 2003, Molecular cell.

[13]  J. Chirgwin,et al.  Transforming growth factor-beta in osteolytic breast cancer bone metastases. , 2003, Clinical orthopaedics and related research.

[14]  Klaus Pantel,et al.  Molecular signature associated with bone marrow micrometastasis in human breast cancer. , 2003, Cancer research.

[15]  L. Wakefield,et al.  The two faces of transforming growth factor β in carcinogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Massagué,et al.  Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus , 2003, Cell.

[17]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[18]  C. Heldin,et al.  Elucidation of Smad Requirement in Transforming Growth Factor-β Type I Receptor-induced Responses* , 2003, The Journal of Biological Chemistry.

[19]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[20]  Ying E. Zhang,et al.  TGF‐β receptor‐activated p38 MAP kinase mediates Smad‐independent TGF‐β responses , 2002 .

[21]  A. Balmain,et al.  Metastasis is driven by sequential elevation of H-ras and Smad2 levels , 2002, Nature Cell Biology.

[22]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[23]  M. Goumans,et al.  Regulation of cell proliferation by Smad proteins , 2002, Journal of cellular physiology.

[24]  M. Karperien,et al.  Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. , 2002, The American journal of pathology.

[25]  Paul J. Williams,et al.  A Bone‐Seeking Clone Exhibits Different Biological Properties from the MDA‐MB‐231 Parental Human Breast Cancer Cells and a Brain‐Seeking Clone In Vivo and In Vitro , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  H. Vloedgraven,et al.  Monitoring Metastatic Behavior of Human Tumor Cells in Mice with Species‐Specific Polymerase Chain Reaction: Elevated Expression of Angiogenesis and Bone Resorption Stimulators by Breast Cancer in Bone Metastases , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  H. Moses,et al.  Phosphatidylinositol 3-Kinase Function Is Required for Transforming Growth Factor β-mediated Epithelial to Mesenchymal Transition and Cell Migration* , 2000, The Journal of Biological Chemistry.

[28]  A. Schulze,et al.  Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. , 2000, Genes & development.

[29]  S. Bull,et al.  Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. , 2000, The New England journal of medicine.

[30]  C. Heldin,et al.  TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. , 1999, Journal of cell science.

[31]  Xin Chen,et al.  The Role of FAST-1 and Smads in Transcriptional Regulation by Activin during Early Xenopus Embryogenesis* , 1999, The Journal of Biological Chemistry.

[32]  L. Chung,et al.  Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment , 1999, The Prostate.

[33]  R Wieser,et al.  TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. , 1999, The Journal of clinical investigation.

[34]  C. Heldin,et al.  The L45 loop in type I receptors for TGF‐β family members is a critical determinant in specifying Smad isoform activation , 1998, FEBS letters.

[35]  Denis Vivien,et al.  Direct binding of Smad3 and Smad4 to critical TGFβ‐inducible elements in the promoter of human plasminogen activator inhibitor‐type 1 gene , 1998, The EMBO journal.

[36]  Allan Balmain,et al.  TGFβ1 Inhibits the Formation of Benign Skin Tumors, but Enhances Progression to Invasive Spindle Carcinomas in Transgenic Mice , 1996, Cell.

[37]  R. Derynck,et al.  TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors , 1994, The Journal of cell biology.

[38]  L. Weiss.  Comments on hematogenous metastatic patterns in humans as revealed by autopsy , 1992, Clinical & Experimental Metastasis.

[39]  M. Burger,et al.  Why do cancer cells metastasize into particular organs? , 1992, BioEssays : news and reviews in molecular, cellular and developmental biology.

[40]  R. Baggs,et al.  A murine model of experimental metastasis to bone and bone marrow. , 1988, Cancer research.

[41]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[42]  R. Cardiff,et al.  Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Quintanilla,et al.  Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. , 2003, The Journal of biological chemistry.

[44]  H. Moses,et al.  Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. , 2001, Molecular biology of the cell.

[45]  M. Hendrix,et al.  Invasion and metastasis of a mammary tumor involves TGF‐β signaling , 2001 .

[46]  E. Hay.  An overview of epithelio-mesenchymal transformation. , 1995, Acta anatomica.